ArticleApplied biochemistry and biotechnology2026
Oleuropein Regulates GSDME Methylation to Inhibit Tumor Growth and Enhance Radiosensitivity in Head and Neck Squamous Cell Carcinoma Via Inducing Pyroptosis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Radiotherapy (RT) is the most common nonsurgical treatment for head and neck squamous cell carcinoma (HNSCC), while HNSCC was insensitive to RT, which is the primary cause of treatment failure. Thus, exploring the novel molecular mechanisms of HNSCC progression may help to increase tumor radiosensitivity. Previous studies have revealed the induction of apoptosis in anti-tumor treatment with oleuropein; while the effect of oleuropein on pyroptosis is unclear. This study explored the effect of oleuropein on HNSCC and the underlying mechanisms in HNSCC cells and HNSCC mice. HNSCC cells were exposed to central irradiation at 5 Gy with 6MV-X-ray to mimic cell RT, and HNSCC mice received a dose of 12 Gy on days 7 and 14 to mimic the in vivo RT. Cell proliferation and apoptosis were assessed via cell counting Kit-8 assay and flow cytometry; RNA expression and protein levels were detected via quantitative real time-polymerase chain reaction (PCR) and western blotting; gasdermin E (GSDME) promoter methylation level was assessed by Methylation-specific PCR and MassARRAY assay; tumor growth and death were assessed via Ki67 immunohistochemical staining and terminal deoxynucleotidyl Transferase Mediated Nick End Labeling staining; pathological changes in tumor tissues was assessed via hematoxylin-eosin staining. The results showed that oleuropein inhibited cell proliferation and enhanced radiosensitivity by inducing caspase3/GSDME-N-dependent pyroptosis in HNSCC cells. Additionally, oleuropein up-regulated miR-194-5p expression and miR-194-5p inhibitor reversed the suppression of cell proliferation induced by oleuropein. Mechanistically, miR-194-5p targeted DNMT3A to affect GSDME promoter methylation, thereby regulating GSDME expression to affect pyroptosis. In vivo experiments further demonstrated that oleuropein blocked tumor growth and enhanced radiosensitivity in HNSCC. In conclusion, these results provide an experimental basis for the application of oleuropein in HNSCC treatment.
Indexed as
Identifiers
42274874What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.